Video

Biosimilars Poised to Impact Specialty Pharmacy

Author(s):

Davy James, Managing Editor

Amy Grogg, PharmD, senior vice president of Strategy and Commercialization at AmerisourceBergen Specialty Group, discusses the projected ramifications from the launch of biosimilars in the United States.

Amy Grogg, PharmD, senior vice president of Strategy and Commercialization at AmerisourceBergen Specialty Group, discusses the projected ramifications from the launch of biosimilars in the United States.

This video was recorded courtesy of Armada Health Care at the 2015 Armada Specialty Pharmacy Summit in Las Vegas, Nevada.

Related Videos
California Wildfires, Pharmacies, Community | image Credit: J Bettencourt/peopleimages.com | stock.adobe.com
California Wildfire, Pharmacy, Community | Image Credit: Erin | stock.adobe.com
Allergies, Asthma, Biologic Treatment, Pharmacists | Image Credit: Pixel-Shot | stock.adobe.com
Related Content
Close up of a biogeneric drugs syringe filled with red and yellow pills - Image credit: javu | stock.adobe.com
January 29th 2025

FDA Accepts Review of Biologics License Application for AVT05, a Biosimilar Candidate for Golimumab

Kennedy Ferruggia, Assistant Editor
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

Chronic kidney disease diagnosis papers -- Image credit: Zerbor | stock.adobe.com
January 29th 2025

Iron Deficiency Is Prevalent in Patients With Non-Anemia, Non-Dialysis-Dependent-CKD

Gillian McGovern, Associate Editor
Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer
October 28th 2024

Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer

Advances in Dermatomyositis Treatment
January 28th 2025

Patients With Juvenile Dermatomyositis Treated With IVIG Had No Increased Risk of Thromboembolic Events

Luke Halpern, Assistant Editor
Ozempic and Wegovy semaglutide pens with pink tape measure
Published: January 28th 2025 | Updated: January 28th 2025

FDA Approves Semaglutide to Reduce Kidney Disease, Cardiovascular Death Risk in Adults With Type 2 Diabetes, Chronic Kidney Disease

Luke Halpern, Assistant Editor